-+ 0.00%
-+ 0.00%
-+ 0.00%

REGENXBIO shares fell 25% in the premarket as the US FDA suspended the company's clinical trial of gene therapy for Hunter syndrome.

Zhitongcaijing·08/24/2026 11:49:06
Listen to the news
REGENXBIO shares fell 25% in the premarket as the US FDA suspended the company's clinical trial of gene therapy for Hunter syndrome.